Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$68.86 USD
+3.79 (5.82%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $69.50 +0.64 (0.93%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for Viking Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 101 | 70 | 56 | 43 | 33 |
Income After Depreciation & Amortization | -101 | -70 | -56 | -43 | -33 |
Non-Operating Income | 15 | 1 | 1 | 3 | 7 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -86 | -69 | -55 | -40 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -86 | -69 | -55 | -40 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -86 | -69 | -55 | -40 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -109 | -69 | -51 | -38 | -32 |
Depreciation & Amortization (Cash Flow) | -8 | 2 | 4 | 4 | 1 |
Income After Depreciation & Amortization | -101 | -70 | -56 | -43 | -33 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 94.35 | 76.83 | 77.20 | 72.60 | 71.96 |
Diluted EPS Before Non-Recurring Items | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 |
Diluted Net EPS (GAAP) | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 |
Fiscal Year end for Viking Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 29.28 | 27.27 | 23.74 | 20.54 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -29.28 | -27.27 | -23.74 | -20.54 |
Non-Operating Income | NA | 4.68 | 4.73 | 4.52 | 1.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -24.60 | -22.53 | -19.23 | -19.53 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -24.60 | -22.53 | -19.23 | -19.53 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -24.60 | -22.53 | -19.23 | -19.53 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 94.35 | 99.85 | 99.01 | 78.35 |
Diluted EPS Before Non-Recurring Items | NA | -0.25 | -0.23 | -0.19 | -0.25 |
Diluted Net EPS (GAAP) | NA | -0.24 | -0.23 | -0.19 | -0.25 |